Electromed, Inc. logo

Electromed, Inc.

ELMD

AMEXHealthcareMedical - Devices

Previous close

$39.45

−$0.55 · -1.37%

Aug 21, 4:00 PM ET

ELMD company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Buy

Favorable setup — positive multi-factor alignment

Valuation

85

Deep Value

Momentum

92

Strong Up

Sentiment

50

Mixed

Risk resilience

70

Moderate Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

Electromed, Inc. develops, manufactures, markets, and sells airway clearance therapy and related products that apply high frequency chest wall oscillation (HFCWO) therapy in pulmonary care for patients in the United States and internationally. The company offers SmartVest airway clearance system for patients with compromised pulmonary functions, including bronchiectasis and cystic fibrosis, as well as neuromuscular conditions, such as cerebral palsy, muscular dystrophies, amyotrophic lateral sclerosis, and post-surgical complications; SmartVest SQL System; SmartVest Clearway System that consists of an inflatable therapy garment, a programmable air pulse generator, and a patented single-hose that delivers air pulses from the generator to the garment to create oscillatory pressure on the chest wall; and SmartVest Connect, a wireless technology that allows data connection between physicians and patients to track therapy performance and collaborate in treatment decisions. It also provides single patient use SmartVest and SmartVest Wrap products for health care providers in the acute care setting. It markets its products to physicians, health care providers, and directly to patients. Electromed, Inc. was incorporated in 1992 and is headquartered in New Prague, Minnesota.

Industry
Medical - Devices
Sector
Healthcare
Headquarters
US
CEO
James L. Cunniff
Listed since
Aug 13, 2010
Employees
179

Market position

Day range

Current $39.45

52-week range

Current $39.45

Open
$40.00
Previous close
$40.00
Volume
157.03K
1.96× average
Average volume
80.03K
Average daily volume
Market cap
326.65M USD
Beta
0.51
Market reference 1
50-day average
$41.2624
-4.39% below average
200-day average
$31.1066
+26.82% above average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

P/E (TTM)
32.34×
P/B (TTM)
6.59×
P/S (TTM)
4.55×
Dividend yield
0.00%

Profitability & efficiency

Gross margin
78.44%
Operating margin
18.55%
Net margin
14.08%

Financial health

Debt / equity

Earnings

EPS beat rate
91%
10 beats, 1 miss, 0 met estimates
Average EPS surprise
+56.78%
11 comparable reports
Latest EPS result
0.35
Estimate 0.26 · Beat by 34.62%

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly EPS actual values compared with estimates0.390.270.150.03Q4 '24BeatQ1 '25BeatQ2 '25BeatQ3 '25BeatQ4 '25BeatQ1 '26BeatQ2 '26BeatQ3 '26Estimate
Q4 2024, reported Nov 12, 2024: actual 0.16, estimate 0.03, surprise +433.33%, Beat. Q1 2025, reported Feb 11, 2025: actual 0.22, estimate 0.18, surprise +22.22%, Beat. Q2 2025, reported May 13, 2025: actual 0.21, estimate 0.2, surprise +5.00%, Beat. Q3 2025, reported Aug 26, 2025: actual 0.25, estimate 0.22, surprise +13.64%, Beat. Q4 2025, reported Nov 12, 2025: actual 0.25, estimate 0.22, surprise +13.64%, Beat. Q1 2026, reported Feb 10, 2026: actual 0.32, estimate 0.27, surprise +18.52%, Beat. Q2 2026, reported May 12, 2026: actual 0.35, estimate 0.26, surprise +34.62%, Beat. Q3 2026, reported Aug 25, 2026: actual —, estimate 0.32, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly Revenue actual values compared with estimates20.11M17.65M15.19M12.73MQ4 '24BeatQ1 '25BeatQ2 '25MissQ3 '25BeatQ4 '25MissQ1 '26BeatQ2 '26BeatQ3 '26Estimate
Q4 2024, reported Nov 12, 2024: actual 14.67M USD, estimate 13.5M USD, surprise +8.65%, Beat. Q1 2025, reported Feb 11, 2025: actual 16.26M USD, estimate 15.3M USD, surprise +6.24%, Beat. Q2 2025, reported May 13, 2025: actual 15.68M USD, estimate 16.65M USD, surprise -5.80%, Miss. Q3 2025, reported Aug 26, 2025: actual 17.39M USD, estimate 16.34M USD, surprise +6.44%, Beat. Q4 2025, reported Nov 12, 2025: actual 16.89M USD, estimate 18.3M USD, surprise -7.72%, Miss. Q1 2026, reported Feb 10, 2026: actual 18.9M USD, estimate 18.05M USD, surprise +4.70%, Beat. Q2 2026, reported May 12, 2026: actual 18.58M USD, estimate 17.6M USD, surprise +5.54%, Beat. Q3 2026, reported Aug 25, 2026: actual —, estimate 19.33M USD, surprise —, Comparison unavailable.

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Recent analyst actions

3 institutions
B. Riley SecuritiesmaintainBuy

ETFs holding ELMD

Funds reporting this stock among their holdings, ordered by reported position size.

Continue in GoAI

Research ELMD

research.disclaimer